

## Special Issue

# New Insights into Gut Hormones and Intestinal Diseases

### Message from the Guest Editor

It has been evident for some years now that the intestinotrophic hormone glucagon-like peptide-2 (GLP-2) secreted from the entero-endocrine L cells, has therapeutic potential in treating intestinal diseases. Indeed, the GLP-2 analogue teduglutide is available for the treatment of short bowel syndrome. However, in recent years, it has been recognized that this is probably not the only hormone secreted from the gut implicated in either the pathogenesis or the adaptive and regenerating response in the intestines. In this Special Issue, we wish to focus on all new aspects of the topic of gut hormones and intestinal diseases. Intestinal diseases in this setting include a wide range of conditions, such as short bowel syndrome, inflammatory bowel diseases, cancer, inherited diseases, and intestinal toxicities from other treatments. Suggested topics could be how intestinal disease influences the secretion of gut hormones; if and how these hormones contribute to the pathophysiology, and if the manipulation of gut hormone secretion modifies disease control.

---

### Guest Editor

Dr. Hannelouise Kissow

University of Copenhagen, Faculty of Health Sciences, Copenhagen, Denmark

---

### Deadline for manuscript submissions

closed (31 January 2021)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/si/55265](https://mdpi.com/si/55265)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).